MDS Clinical Discussion Series Online Post-Test
|The Lower-Risk Elderly MDS Patient: Clinical Challenges and Opportunities|
Mikkael A. Sekeres, MD, MS
|Release Date: March 23, 2016|
Expiration Date: March 27, 2016
Advances in our knowledge of genetic abnormalities associated with MDS, as well as advances in diagnosis and risk stratification, are improving the ability of community oncologists to individualize treatment to each patient’s disease. The majority of patients diagnosed with MDS are elderly, and often have potentially significant comorbidities, which often complicate the development of appropriate and effective treatment. Significant progress has been made in the treatment of MDS, however, with three drugs currently approved specifically for the treatment of this disease.Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation